Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin–Angiotensin System on Proteinuria in Renal Disease
Annals of Internal MedicinePublished 1 January 2008
Regina Kunz, Chris Friedrich, Marcel Wolbers, Johannes F.E. Mann
Citations712
SJR quartileQ1
SJR score3.38
SNIP3.27
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
A systematic review and meta-analysis of the effects of ARBs on urinary protein excretion in patients with nephropathy compared with placebo and other antihypertensive agents and their combinations showed that ARBs delay progression of proteinuria over the short (1 to 4 months) and longer (5 to 12 months) terms.
Abstract
The ARBs reduce proteinuria, independent of the degree of proteinuria and of underlying disease. The magnitude of effect is similar regardless of whether the comparator is placebo or calcium-channel blocker. Reduction in proteinuria from ARBs and ACE inhibitors is similar, but their combination is more effective than either drug alone. Uncertainty concerning adverse effects and outcomes that are important to patients limits applicability of findings to clinical practice.
Keywords
Medicine
BMJMeasuring inconsistency in meta-analyses
62,756 Citations2003Julian P. T. Higgins, Simon G. Thompson +2 more
A new quantity is developed, I 2, which the authors believe gives a better measure of the consistency between trials in a meta-analysis, which is susceptible to the number of trials included in the meta- analysis.
Statistics in MedicineQuantifying heterogeneity in a meta‐analysis
36,744 Citations2002Julian P. T. Higgins, Simon G. Thompson
It is concluded that H and I2, which can usually be calculated for published meta-analyses, are particularly useful summaries of the impact of heterogeneity, and one or both should be presented in publishedMeta-an analyses in preference to the test for heterogeneity.
Data Archiving and Networked Services (DANS)K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
11,656 Citations2002Andrew S. Levey, Josef Coresh +77 more
BMC Medical Research MethodologyEstimating the mean and variance from the median, range, and the size of a sample
9,135 Citations2005Stela Pudar Hozo, Benjamin Djulbegović +1 more
New England Journal of MedicineThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
8,985 Citations1999Bertram Pitt, Faı̈ez Zannad +6 more
Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure.
New England Journal of MedicineEffects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy
7,484 Citations2001Barry M. Brenner, Mark E. Cooper +8 more
Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally well tolerated.
New England Journal of MedicineRenoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes
5,920 Citations2001Edmund J. Lewis, Lawrence G. Hunsicker +8 more
The angiotensin-II-receptor blocker irbesartan is effective in protecting against the progression of nephropathy due to type 2 diabetes, independent of the reduction in blood pressure it causes.
BiometricsThe Combination of Estimates from Different Experiments
5,203 Citations1954William G. Cochran
The LancetImproving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement
4,808 Citations1999David Moher, Fadi Hammal +4 more
This report hopes this report will generate further thought about ways to improve the quality of reports of meta-analyses of RCTs and that interested readers, reviewers, researchers, and editors will use the QUOROM statement and generate ideas for its improvement.
New England Journal of MedicineThe Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes
2,865 Citations2001Masanori Wakisaka, Hendrik Lehnert +4 more
Irbesartan is renoprotective independently of its blood-pressure-lowering effect in patients with type 2 diabetes and microalbuminuria, and serious adverse events were less frequent among the patients treated with the drug.
PubMed[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
2,529 Citations2001Hans‐Henrik Parving, Hendrik Lehnert +4 more
Irbesartan is renoprotective independently of its blood pressure lowering effect in type 2 diabetic subjects with microalbuminuria and is safe and well tolerated.
International Journal of EpidemiologyMeta-analyses involving cross-over trials: methodological issues
2,294 Citations2002Diana R Elbourne, Douglas G. Altman +4 more
Methods do exist for including valuable information from two-period, two-treatment cross-over trials into quantitative reviews, however, poor reporting of cross- over trials will often impede attempts to perform a meta-analysis using the available methods.
Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta‐Analysis
2,137 Citations2001Jonathan J Deeks, Douglas G. Altman +1 more
BMJThe case of the misleading funnel plot
1,758 Citations2006Joseph Lau, John P. A. Ioannidis +3 more
Evidence based medicine insists on rigorous standards to appraise clinical interventions, and failure to apply the same rules to its own tools could be equally damaging.
New England Journal of MedicineRates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study
1,752 Citations2004David N. Juurlink, Muhammad Mamdani +5 more
The publication of RALES was associated with abrupt increases in the rate of prescriptions for spironolactone and in hyperkalemia-associated morbidity and mortality and closer laboratory monitoring and more judicious use of spironOLactone may reduce the occurrence of this complication.
Annals of Internal MedicineAngiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease
1,093 Citations2001Tazeen H. Jafar, Christopher H. Schmid +18 more
Antihypertensive regimens that include ACE inhibitors are more effective than regimens without ACE inhibitors in slowing the progression of nondiabetic renal disease and is greater in patients with proteinuria.
BMJRandomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study
1,039 Citations2000C. E. Mogensen, Steen Neldam +5 more
Cadesartan 16 mg once daily is as effective as lisinopril 20 mgonce daily in reducing blood pressure and microalbuminuria in hypertensive patients with type 2 diabetes and combination treatment is well tolerated and more effective in reducingBlood pressure.
The LancetRETRACTED: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial
977 Citations2003Naoyuki Nakao, Ashio Yoshimura +4 more
Combination treatment safely retards progression of non-diabetic renal disease compared with monotherapy, however, since some patients reached the combined primary endpoint on combined treatment, further strategies for complete management of progressive nondi diabetic renal disease need to be researched.
Kidney InternationalProteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL
970 Citations2004Dick de Zeeuw, Giuseppe Remuzzi +8 more
Albuminuria is the predominant renal risk marker in patients with type 2 diabetic nephropathy on conventional treatment; the higher the albuminuria, the greater the renal risk and the stronger the renal protection.
New England Journal of MedicineAngiotensin-Receptor Blockade versus Converting–Enzyme Inhibition in Type 2 Diabetes and Nephropathy
912 Citations2004Anthony Barnett, Stephen C. Bain +5 more
Telmisartan is not inferior to enalapril in providing long-term renoprotection in persons with type 2 diabetes and early nephropathy, and these findings support the clinical equivalence of angiotensin II-receptor blockers and ACE inhibitors in people with conditions that place them at high risk for cardiovascular events.
CirculationMicroalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus
807 Citations2002Giancarlo Viberti, Nigel Wheeldon
Journal of Clinical InvestigationMechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes
617 Citations2006Giuseppe Remuzzi
PubMedCompleteness of safety reporting in randomized trials: an evaluation of 7 medical areas.
568 Citations2001John P. A. Ioannidis, Joseph Lau
Current standards for safety reporting in randomized trials should be revised to address this inadequacy, as generalizable data on drug safety reporting are sparse and largely inadequate.
Annals of Internal MedicineMeta-Analysis: Low-Dose Dopamine Increases Urine Output but Does Not Prevent Renal Dysfunction or Death
512 Citations2005Jan O. Friedrich, Neill K. J. Adhikari +2 more
A systematic review and meta-analysis of low-dose dopamine was conducted by using a comprehensive search strategy to determine its effect on a broad range of clinical and renal physiologic outcomes and adverse events.
American Journal of Kidney DiseasesProteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy
366 Citations2005Robert C. Atkins, Esther M. Briganti +9 more
Baseline proteinuria is an important risk factor for kidney failure and provides a means to identify patients at greatest risk and proteinuria reduction using an angiotensin receptor-blocking agent, such as irbesartan, should be regarded as an important therapeutic goal in renoprotective strategies.
Kidney InternationalIs the antiproteinuric effect of ACE inhibition mediated by intereference in the renin-angiotensin system?
296 Citations1994Ron T. Gansevoort, Dick de Zeeuw +1 more
The effects of specific intervention in the renin-angiotensin system with the Ang II receptor antagonist losartan and enalapril were investigated and compared these effects to those obtained with ACE inhibition, as this comparison might resolve the question whether or not the effects of ACE inhibition are Ang II related.
Kidney InternationalRenoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy
284 Citations2000Steen Andersen, Lise Tarnow +3 more
The results indicate that the reduction in albuminuria and blood pressure during ACE inhibition is primarily caused by interference in the renin-angiotensin system and suggests that losartan represents a valuable new drug in the treatment of hypertension and proteinuria in type 1 diabetic patients with diabetic nephropathy.
American Journal of Kidney DiseasesCoadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy
243 Citations2001Domenico Russo, Roberto Minutolo +5 more
This study shows that combination therapy with E and LOS has an additive dose-dependent antiproteinuric effect that is likely induced by the drug-related reduction in systemic blood pressure.
Kidney InternationalLong-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy
229 Citations2000Yves Lacourciére, André Bélanger +5 more
It is indicated that a one-year course of antihypertensive therapy with either losartan or enalapril significantly reduces UAE in hypertensive type 2 diabetic patients with early nephropathy.
Kidney InternationalDual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy
229 Citations2003Peter Karl Jacobsen, Steen Andersen +3 more
Dual blockade of the RAS is superior to maximal recommended dose of ACE inhibitors with regard to lowering of albuminuria and blood pressure in type 1 patients with DN and was safe and well tolerated.
Diabetes CareRenoprotective Effects of Adding Angiotensin II Receptor Blocker to Maximal Recommended Doses of ACE Inhibitor in Diabetic Nephropathy
226 Citations2003Kasper Rossing, Peter Karl Jacobsen +2 more
Dual blockade of the RAS provides superior short-term renoprotection independent of systemic blood pressure changes in comparison with maximally recommended doses of ACEI in patients with type 2 diabetes as well as nephropathy.
Journal of the American Society of NephrologyManagement of Glomerular Proteinuria
221 Citations2003William A. Wilmer, Brad H. Rovin +4 more
It is suggested that, until better information becomes available, a broad-based, multiple-risk factor intervention to reduce proteinuria can be justified in those with progressive nephropathies.
American Journal of Kidney DiseasesHong Kong Study Using Valsartan in IgA Nephropathy (HKVIN): A Double-Blind, Randomized, Placebo-Controlled Study
214 Citations2006Philip Kam‐Tao Li, Chi Bon Leung +10 more
Journal of the American Society of NephrologyAdditive Effect of ACE Inhibition and Angiotensin II Receptor Blockade in Type I Diabetic Patients with Diabetic Nephropathy
209 Citations2003Peter Karl Jacobsen, Steen Andersen +2 more
In conclusion, dual blockade of the RAS may offer additional renal and cardiovascular protection in type I diabetic patients with DN.
Diabetes CareDual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy
205 Citations2002Kasper Rossing, Per K. Christensen +2 more
Dual blockade of the RAS reduces albuminuria and blood pressure in type 2 diabetic patients with DN responding insufficiently to previous antihypertensive therapy, including ACE inhibitors in recommended doses.
Kidney InternationalEffects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies
186 Citations2003Ruth Campbell, Fabio Sangalli +9 more
Long-term combined ACEi and ARA therapy may be more renoprotective than treatment with each agent alone, and the greater antiproteinuric effect most likely depended on an ACEi-related hemodynamic effect, in addition to glomerular size selectivity amelioration.
Journal of HypertensionSafety of the combination of valsartan and benazepril in patients with chronic renal disease
180 Citations2000Luís M. Ruilope, Jean‐Claude Aldigier +4 more
Investigation of the safety and tolerability of the combination of valsartan and benazepril indicates that short-term combination of an angiotensin-converting enzyme inhibitor and an angiotsin receptor blocker is safe and well tolerated in patients with moderate chronic renal failure.
Kidney InternationalDual renin-angiotensin system blockade at optimal doses for proteinuria
169 Citations2002Gozewijn D. Laverman, Gerjan Navis +3 more
Dose-titration with a renin-angiotensin system blocker, followed by add-on therapy is highly effective in order to reduce proteinuria and the safety of this regimen needs to be addressed in future studies.
Journal of the American Society of NephrologyAdditional Antiproteinuric Effect of Ultrahigh Dose Candesartan
151 Citations2005Roland E. Schmieder, Arnfried U. Klingbeil +3 more
The data indicate an additive antiproteinuric effect of ultrahigh dose of the angiotensin receptor blocker candesartan compared with standard dose.
Kidney InternationalAdd-on angiotensin receptor blockade with maximized ACE inhibition
130 Citations2001Rajiv Agarwal
Improvement of GFR and fall in plasma renin activity suggest that renal hemodynamic and endocrine changes are more sensitive measures of AT1 receptor blockade.
Journal of the American Society of NephrologyACE Inhibitors versus AT1 Receptor Antagonists in Patients with Chronic Renal Disease
128 Citations2002Karl F. Hilgers, Johannes F.E. Mann
The success of Angiotensin-converting enzyme (ACE) inhibitors in preventing the progression of chronic renal insufficiency has led investigators to study the effects of other inhibitors of the renin-angiotenin system (RAS).
Nephrology Dialysis TransplantationDual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy
126 Citations2002Peter Karl Jacobsen
Dual blockade of the RAS may offer additional renal and cardiovascular protection in type 1 patients with DN responding insufficiently to conventional antihypertensive therapy, including recommended doses of ACEI and diuretics.
Journal of HypertensionAdditive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade
125 Citations2002Paolo Ferrari, Hans‐Peter Marti +2 more
A combination of ACEI and ARB in patients with glomerulonephritis produces a more profound decrease in proteinuria than either drug alone, and this additive antiproteinuric effect is not dependent on changes in blood pressure or creatinine clearance.
Journal of the American Society of NephrologyDiuretic and Enhanced Sodium Restriction Results in Improved Antiproteinuric Response to RAS Blocking Agents
121 Citations2004Vincent Esnault, A. Ekhlas +3 more
In patients with severe proteinuria and hypertension, a cautious increase in diuretic dosage in addition to combined angiotensin-converting enzyme inhibitors and angiotENSin receptor blockers decreasesproteinuria and BP but may expose the patient to prerenal failure.
Statistics in MedicineMeta‐analysis combining parallel and cross‐over clinical trials. III: The issue of carry‐over
120 Citations2002François Curtin, Diana Elbourne +1 more
A method based on a multivariate analysis of the meta‐analytic treatment effect and carry‐over estimates is proposed, which investigates simultaneously the statistical significance of these two estimators as well as the carry-over at meta‐analysis level.
Current Therapeutic ResearchThe effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial
87 Citations1999Norman Muirhead, Brian F. Feagan +7 more
It is suggested that treatment with valsartan slows the progressive rise of AER in normotensive and treated hypertensive patients with type 2 diabetes mellitus with comparable efficacy and superior tolerability to captropril.
Nephrology Dialysis TransplantationRandomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria
85 Citations2002Priscilla Kincaid‐Smith, K. F. Fairley +1 more
The addition of 8 mg of Candesartan in normotensive patients with chronic renal disease and proteinuria receiving an ACEI appeared safe and was not accompanied by adverse effects apart from postural hypotension in three patients and a serum potassium level of 6.3 mmol/l in one.
ACC Current Journal ReviewCombination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial
85 Citations2003Naoyuki Nakao, Ashio Yoshimura +4 more
Combination treatment safely retards progression of non-diabetic renal disease compared with monotherapy, however, since some patients reached the combined primary endpoint on combined treatment, further strategies for complete management of progressivenon-di diabetic renal disease need to be researched.
Diabetes Research and Clinical PracticeBeneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension
82 Citations2005Ahmet M. Şengül, Yüksel Altuntaş +2 more
It is concluded that use of dual blockade may provide a new approach to prevention of diabetic nephropathy in patients with type 2 diabetes, hypertension and microalbuminuria by providing superior blood pressure and AER control than either monotherapy.
Kidney InternationalEffects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies
77 Citations2002José Luño, V. Barrio +9 more
Dual blockade of the renin-angiotensin system with ACE inhibitors and AT1 receptor blockers produces a beneficial antiproteinuric effect that could not be explained only by the systemic blood pressure reduction.
Nephron Clinical PracticeCalcium Channel Blocker versus Angiotensin II Receptor Blocker in Autosomal Dominant Polycystic Kidney Disease
77 Citations2005Kikuo Nutahara, Eiji Higashihara +9 more
The renoprotective effect of candesartan is considered more favorable than amlodipine in the treatment of ADPKD, independent of the antihypertensive effect per se.
Hypertension ResearchRenoprotective Effect of Losartan in Comparison to Amlodipine in Patients with Chronic Kidney Disease and Hypertension-a Report of the Japanese Losartan Therapy Intended for the Global Renal Protection Hypertensive Patients (JLIGHT) Study
76 Citations2004Yasuhiko Iino, Matsuhiko Hayashi +15 more
Losartan reduced proteinuria in patients with CKD and hypertension, and this positive effect may contribute to the renal protective benefit of losartan, and is beyond the magnitude of BP control.
Diabetes CareOptimal Dose of Candesartan for Renoprotection in Type 2 Diabetic Patients With Nephropathy
75 Citations2003Kasper Rossing, Per K. Christensen +3 more
The optimal dose of candesartan is 16 mg daily for renoprotection, as reflected by short-term reduction in albuminuria, in hypertensive type 2 diabetic patients with nephropathy.
Diabetes CareIrbesartan Reduces the Albumin Excretion Rate in Microalbuminuric Type 2 Diabetic Patients Independently of Hypertension
72 Citations2002Ferdinando Carlo Sasso, Ornella Carbonara +6 more
In microalbuminuric hypertensive type 2 diabetic subjects, irbesartan reduced 24-h mean systolic and diastolic pressure and AER and these results indicate the beneficial effects of irbesARTan on AER in type 2 diabetes subjects, independently of its antihypertensive effects.
Annals of Internal MedicineEffect of Losartan on Microalbuminuria in Normotensive Patients with Type 2 Diabetes Mellitus
71 Citations2003Adrienne A.M. Zandbergen, M.G.A. Baggen +4 more
This 10-week randomized, placebo-controlled trial showed that in normotensive diabetic patients receiving losartan, albumin excretion rate was significantly reduced and blood pressure slightly decreased, and angiotensin-receptor antagonists hold promise in preserving renal function in patients with type 2 diabetes without marked hypertension, but they warrant further study.
Nephrology Dialysis TransplantationEffect of low-dose dual blockade of renin–angiotensin system on urinary TGF-β in type 2 diabetic patients with advanced kidney disease
63 Citations2005Joon Ho Song, Seok Ho +5 more
The dual blockade of RAS with low-dose ramipril plus candesartan was found to be safe and offered additive benefits with respect to reducing proteinuria and urinary TGF-beta1 excretion in diabetic patients with advanced kidney disease.
Nephrology Dialysis TransplantationRenal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy
62 Citations1998Hallvard Holdaas, A. Hartmann +3 more
It is demonstrated that losartan, but not amlodipine, decreased albumin excretion in hypertensive patients with non-diabetic nephropathy.
Hypertension ResearchLow-Dose Combination Therapy with Temocapril and Losartan Reduces Proteinuria in Normotensive Patients with Immunoglobulin A Nephropathy
59 Citations2004Yoshio Horita, Masato Tadokoro +5 more
The effectiveness of the combined therapy may have been at least partly due to the greater inhibition of the action of angiotensin II in patients with IgA nephropathy.
Nephrology Dialysis TransplantationEffect of losartan and amlodipine on proteinuria and transforming growth factor- 1 in patients with IgA nephropathy
58 Citations2003Hyeong Cheon Park, Zhiguo Xu +7 more
Nephrology Dialysis TransplantationAntiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial
57 Citations2003Manuel Praga
Losartan induced a drastic decrease in proteinuria accompanied by a reduction in urinary excretion of TGF-beta in patients with non-diabetic proteinuric renal diseases and predicts long-term renoprotection afforded by these drugs.
American Journal of Kidney DiseasesLow-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis
56 Citations2004Przemysław Rutkowski, Leszek Tylicki +4 more
The study shows that combination therapy with very small doses of losartan and benazepril was more effective in reducing proteinuria than greater doses of either agent in monotherapy, and this greater antiproteinuric efficacy was independent of changes in BP.
Acta DiabetologicaEfficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study
53 Citations2001Neslihan Başçıl Tütüncü, Alper Gürlek +1 more
ACE inhibitors and angiotensin II receptor blockers have similar efficacy in treating diabetic microalbuminuria, and the combination of the two drugs does not add any further benefit.
Journal of the Renin-Angiotensin-Aldosterone SystemCombination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses
51 Citations2003J. Segura, Manuel Praga +3 more
The antiproteinuric capacity of monotherapy at recommended doses with either an ACE-I or an ARB is lower than that obtained with the combination of the two drugs.
Kidney InternationalBetter renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood
45 Citations2003Anne C. Gartenmann, Emilio Fossali +5 more
The study demonstrates that in children the effect of angiotensin II antagonists on proteinuria is better than that of dihydropyridine calcium channel blockers.
Journal of HypertensionReduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition
41 Citations2002Elke D. Berger, Birgit Bader +3 more
Cedesartan promotes a complementary antiproteinuric and a small antihypertensive effect after a treatment period of 8 weeks in patients with chronic glomerulonephritis when given in conjunction with an ACEI.
Clinical NephrologyEffects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy
32 Citations2005J P S Matos, Menezes Rodrigues +4 more
Only combined therapy with irbesartan plus perindopril concurrently reduces plasma aldosterone, proteinuria and urinary TGF-beta1.
International Journal of Clinical PracticeAnti-proteinuric effects of combination therapy with enalapril and losartan in patients with nephropathy due to type 2 diabetes
31 Citations2004R Çetinkaya, A.R. Odabas +1 more
It is found that proteinuria reduction induced by combined therapy is maintained throughout short‐term follow‐up; a greater anti‐proteinuric response was observed in the patients with DNP.
Yonsei Medical JournalAdditive Antiproteinuric Effect of Combination Therapy with ACE Inhibitor and Angiotensin II Receptor Antagonist: Differential Short-term Response between IgA Nephropathy and Diabetic Nephropathy
31 Citations2003Moon Jae Kim, Joon Ho Song +3 more
The benefit of combination therapy of its antiproteinuric effect was different between IgA and diabetic nephropathy over the 12-week trial, and it is suggested the discrimination of the underlying renal diseases in the study subjects is an important prerequisite for future studies on this issue.
Scandinavian Journal of Urology and NephrologyLow-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis
28 Citations2004Marcin Renke, Leszek Tylicki +2 more
Diabetes CareEffects of Losartan and Amlodipine on Urinary Albumin Excretion and Ambulatory Blood Pressure in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy
27 Citations2005Gen Yasuda, Daisaku Ando +3 more
The results suggest that in type 2 diabetes with overt nephropathy, 24-h blood pressure regulation alone is inadequate to reduce macroalbuminuria and additional effects of losartan are crucial for antiproteinuric action.
Diabetes Research and Clinical PracticeAntiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy
26 Citations2004Masakazu Haneda, Ryuichi Kikkawa +2 more
Results indicate that candesartan cilexetil is useful in reducing proteinuria in diabetic subjects when compared with placebo and seems to be effective in subjects with both the II and DD genotypes of the ACE gene.
Hypertension ResearchDiffering Anti-Proteinuric Action of Candesartan and Losartan in Chronic Renal Disease
23 Citations2003Hiroto Matsuda, Kôichi Hayashi +7 more
Hypertension ResearchEffects of Valsartan on the Progression of Chronic Renal Insufficiency in Patients with Nondiabetic Renal Diseases
17 Citations2005Toshihiko Ishimitsu, Tomoko Kameda +10 more
It is possible that long-term treatment with an angiotensin II receptor blocker, valsartan, is effective at retarding the deterioration of renal function in patients with nondiabetic renal disease by a mechanism independent of blood pressure reduction.
PubMedRandomized, controlled study of the effects of losartan versus enalapril in small doses on proteinuria and tubular injury in primary glomerulonephritis.
11 Citations2005Leszek Tylicki, Marcin Renke +3 more
50 mg of losartan seems to be the minimal dose to improve tubular status, and there were no differences between the drugs regarding their influence on tubular injury extent.
Clinical Drug InvestigationTolerability and Antihypertensive Efficacy of Losartan vs Captopril in Patients with Mild to Moderate Hypertension and Impaired Renal Function
3 Citations2000Egbert G. Schulz, Jesper Nørgaard Bech +4 more
Losartan could be as suitable as captopril as an antihypertensive agent in cases where renal function is impaired, and total proteinuria was significantly decreased at the end of the study.
…